Biologic Therapy for Psoriasis: An Update on the Tumor Necrosis Factor Inhibitors Infliximab, Etanercept, and Adalimumab, and the T-Cell-Targeted Therapies Efalizumab and Alefacept

September 2005 | Volume 4 | Issue 5 | Original Article | 544 | Copyright © 2005

Jeffrey M. Weinberg MD, Clement J. Bottino BA, James Lindholm BA, Robin Buchholz MD


Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to update the progress of the tumor necrosis inhibitors which are available, or under investigation, for clinical use in psoriasis: infliximab, etanercept, and adalimumab, as well as the T-cell-targeted therapies efalizumab and alefacept (Table 1).

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

Related Articles